Skip to Content
Upcoming Webinar

Cabozantinib in Previously Treated Neuroendocrine Tumors (NETs)

Date: May 27, 2025 | 2:00 PM

Neuroendocrine tumors (NETs) present unique treatment challenges—especially in the relapsed or previously treated setting. As the role of cabozantinib continues to evolve, care teams are navigating how to apply emerging data in real-world practice.

Join Kirollos Hanna from Minnesota Oncology for a timely discussion on how cabozantinib is being used in NETs today, what the latest data tells us, and how oncology teams can confidently manage therapy and support patients throughout their care.

We’ll cover:

  • Where cabozantinib fits in the NET treatment landscape
  • Clinical efficacy and safety data
  • Adverse reaction management and patient education
  • Resources for providers, patients, and caregivers

 

For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.